Clinical Trial

Characterization of Metabolic Changes in the Glioma Tumor Tissue Induced by Transient Fasting (ERGO3)

Study acronym: ERGO3
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Nutritional interventions such as ketogenic diet (KD) or fasting are currently under evaluation as anti-cancer treatment. In glioma patient cohorts, the feasibility and safety of fasting in addition to antitumor treatment has been shown. However, it is still unclear whether fasting exerts effects on the glioma tumor tissue at all, and whether fasting causes metabolic or immunological changes in the glioma microenvironment that could be exploited therapeutically. Therefore, the central contribution of this study is to characterize metabolic and immunological changes in the glioma tumor tissue induced by a fasting cycle of 72 hours prior to biopsy or resection.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-07-07; most recent amendment 2024-10-15.
Status change: Recruiting → Active, Not Recruiting 2023-03-07
Trial Details
NCT Number NCT04461938
Lead Sponsor Goethe University
Conditions Glioma, Mixed
Enrollment 30 participants
Start Date 2020-08-19
Primary Completion 2022-12-31 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-10-17